Budesonide And Formoterol

Introduction Overview

Generic Name

budesonide and formoterol

Brand Name

Symbicort

Dosage Form

Inhaler (budesonide 80 mcg and formoterol fumarate 4.5 mcg), Inhaler (budesonide 160 mcg and formoterol fumarate 4.5 mcg), Aerosphere inhaler (budesonide 160 mcg and formoterol fumarate 4.8 mcg)

Drug Class

Bronchodilator combinations

Pharmacokinetics

Absorption:
Symbicort combines budesonide, an inhaled corticosteroid, and formoterol fumarate, a long-acting beta2-adrenergic receptor agonist (LABA), delivered via inhalation to maximize local pulmonary effects and minimize systemic exposure. Budesonide is well absorbed through the respiratory tract; peak plasma concentrations occur within 30 minutes after inhalation. Approximately 39% to 59% of the delivered dose is absorbed systemically, reflecting pulmonary absorption and gastrointestinal absorption after swallowing residual drug. Formoterol is rapidly absorbed from the lungs, with peak plasma levels attained roughly 10 minutes after inhalation. The rapid onset of formoterol absorption contributes to its bronchodilatory effects. Both components undergo extensive first-pass metabolism when swallowed, limiting the systemic availability of the swallowed fraction.

Distribution:
Budesonide demonstrates a high volume of distribution (around 3 L/kg), reflecting extensive tissue binding, particularly in the lungs and adipose tissue. Budesonide is approximately 85%-90% protein bound, mainly to albumin, which influences its tissue distribution. Formoterol has a volume of distribution ranging 3-5 L/kg and is about 61% plasma protein bound. Both drugs distribute preferentially to lung tissues, which is critical for their pharmacodynamic effects. Due to inhalation administration, high local concentrations in pulmonary tissues are obtained with lower plasma concentrations, reducing systemic side effects.

Metabolism:
Budesonide is primarily metabolized by hepatic cytochrome P450 isoenzymes CYP3A4 and CYP3A5 through extensive biotransformation into 16α-hydroxy prednisolone and other metabolites with negligible glucocorticoid activity. The metabolism limits systemic corticosteroid exposure, thereby reducing systemic side effects. Formoterol undergoes hepatic metabolism mainly via direct glucuronidation and O-demethylation mediated by CYP enzymes, including CYP2D6. Its metabolites are pharmacologically inactive. Drug interactions involving CYP3A4 inhibitors may influence budesonide exposure, whereas CYP2D6 polymorphisms and inhibitors can influence formoterol metabolism.

Elimination:
Budesonide metabolites are predominantly eliminated via renal excretion, with less than 1% of unchanged budesonide recovered in urine; the elimination half-life ranges from 2 to 3.6 hours after inhalation. Formoterol has an elimination half-life of approximately 10 hours, primarily excreted by the kidneys both as metabolites and unchanged drug. The combination's pharmacokinetic profiles support a twice-daily dosing schedule. No significant accumulation is observed with regular use according to clinical studies, but hepatic impairment can increase systemic exposure necessitating caution.

Dosage Forms

Available Dosage Forms:
- Inhaler with budesonide 80 mcg and formoterol fumarate 4.5 mcg per actuation
- Inhaler with budesonide 160 mcg and formoterol fumarate 4.5 mcg per actuation
- Aerosphere inhaler with budesonide 160 mcg and formoterol fumarate 4.8 mcg per actuation

Dosages for Adults and Adolescents:
- Treatment of asthma in patients 12 years and older: 2 inhalations of Symbicort 80/4.5 mcg or 160/4.5 mcg twice daily, with starting doses selected based on asthma severity.
- Maintenance treatment in chronic obstructive pulmonary disease (COPD): 2 inhalations of Symbicort 160/4.5 mcg twice daily.
- Symbicort Aerosphere inhaler for COPD: inhale 2 actuations of 160/4.8 mcg twice daily.

Dosages for Pediatric Population:
- Treatment of asthma in children aged 6 to less than 12 years: 2 inhalations of Symbicort 80/4.5 mcg twice daily.

Specific Patient Populations:
- Administration dosing may require adjustment based on clinical response.
- Not approved for use in children under 6 years old.
- In patients with hepatic impairment, clearance may be reduced; careful monitoring recommended.

Off-label Use:
- SMART (Single Maintenance And Reliever Therapy): Symbicort used as both maintenance and reliever therapy for moderate to severe persistent asthma, consisting of 1 to 2 puffs 1-2 times daily plus 1-2 puffs as needed for symptom relief; maximum daily dose should not exceed 8 puffs (36 mcg formoterol) for children 4-11 years and 12 puffs (54 mcg formoterol) for those 12 years and older.

Mechanism Of Action

Symbicort is a fixed-dose combination inhaler containing budesonide, an inhaled corticosteroid (ICS), and formoterol, a long-acting β2-adrenergic receptor agonist (LABA), which work synergistically to improve airway function in asthma and COPD.

Budesonide exerts its therapeutic effects primarily through its potent anti-inflammatory properties. It binds intracellular glucocorticoid receptors in airway epithelial cells and inflammatory cells, resulting in altered gene transcription that decreases the production of pro-inflammatory cytokines, chemokines, adhesion molecules, and inflammatory enzymes like cyclooxygenase-2. This leads to reduced recruitment and activation of inflammatory cells such as eosinophils, T-lymphocytes, and mast cells, thereby mitigating airway inflammation, edema, mucus hypersecretion, and hyperresponsiveness characteristic of asthma and COPD.

Formoterol selectively stimulates β2-adrenergic receptors located on airway smooth muscle cells. Activation of β2 receptors increases intracellular cyclic adenosine monophosphate (cAMP) via adenylate cyclase activation. Elevated cAMP activates protein kinase A, leading to phosphorylation and inhibition of myosin light-chain kinase, which causes relaxation of bronchial smooth muscle, resulting in bronchodilation. Formoterol has a rapid onset of action within minutes and prolonged duration lasting approximately 12 hours, which helps maintain bronchodilation and symptomatic relief.

The combined budesonide-formoterol formulation in Symbicort yields additive and complementary effects: budesonide controls chronic inflammation, reducing airway remodeling and hyperreactivity; formoterol provides immediate and sustained bronchodilation improving airflow. Additionally, corticosteroids upregulate β2-adrenergic receptor expression and responsiveness, enhancing formoterol's efficacy. This interplay enhances symptom control and reduces exacerbation frequency. Clinical trials confirm improved lung function, reduced symptom burden, and better quality of life compared to monotherapy with either component. The combination also reduces risks associated with LABA monotherapy in asthma by counteracting potential pro-inflammatory effects through the corticosteroid component.

Pharmacological Actions

Anti-inflammatory action via inhaled corticosteroid budesonide to suppress airway inflammation.
Long-acting bronchodilation mediated by formoterol through β2-adrenergic receptor activation.
Reduction of airway hyperresponsiveness and bronchoconstriction.
Synergistic effect enhancing corticosteroid receptor expression and bronchodilator responsiveness.
Prevention of asthma and COPD exacerbations through combined corticosteroid and LABA action.
Improvement of pulmonary function parameters like FEV1 and peak expiratory flow.
Rapid onset of bronchodilation within 5-15 minutes.
Sustained duration of bronchodilation approximately 12 hours to allow twice daily dosing.
Reduction in mucus secretion and airway edema.
Modulation of inflammatory cell infiltration including eosinophils and lymphocytes.
Decreased cytokine and mediator release from inflammatory cells.
Enhancement of symptom control and reduction of rescue medication use.
Improvement of exercise tolerance and reduction of dyspnea in COPD patients.
Lower systemic corticosteroid exposure due to inhalation delivery.
Suitable for long-term maintenance therapy in asthma and COPD.

Therapeutic Or Clinical Uses

Maintenance treatment of asthma in adults and children aged 6 years and older.
Control and prevention of symptoms in patients with moderate to severe persistent asthma.
Long-term maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
Reduction in frequency and severity of asthma exacerbations.
Improvement in lung function and respiratory symptoms in COPD patients.
Off-label use as SMART therapy (Single Maintenance And Reliever Therapy) in moderate to severe asthma for both maintenance and as-needed relief.
Alternative to separate inhaled corticosteroid and long-acting β2-agonist therapy for convenience and improved adherence.
Improvement of quality of life and exercise tolerance in obstructive airway diseases.
Reduction of rescue inhaler (short-acting β2-agonist) usage.
Potential reduction in hospitalization rates due to better asthma and COPD control.
Management of asthma symptoms unresponsive to monotherapy inhaled corticosteroids.
Prevention of airway remodeling and chronic inflammation progression in asthma.
Suitable for patients inadequately controlled on inhaled corticosteroids alone.
Maintenance therapy adjunct in COPD to reduce exacerbations frequency.
Recommended by guidelines for certain subsets of asthma and COPD patients requiring combined therapy.

Side Or Adverse Effects

Throat irritation or pain and hoarseness due to local corticosteroid effects.
Oropharyngeal candidiasis (thrush) presenting as white patches or soreness in mouth and throat.
Cough and throat dryness immediately after inhalation.
Headache and back pain as common systemic complaints.
Nervousness, tremors, or restlessness related to beta-agonist activity.
Tachycardia, palpitations, and chest discomfort.
Worsening of breathing symptoms or paradoxical bronchospasm, rare but serious.
Blurred vision, eye pain, or redness potentially indicating corticosteroid-related ocular effects.
Elevated blood glucose levels (hyperglycemia), especially in diabetics.
Hypokalemia (low serum potassium) with symptoms like muscle cramps, arrhythmia, or weakness.
Signs of hormonal imbalance such as fatigue, nausea, vomiting, or light-headedness.
Increased susceptibility to infections including pneumonia and respiratory tract infections.
Potential growth suppression in children with long-term corticosteroid use.
Allergic reactions including rash, swelling, or anaphylaxis (rare).
Flu-like symptoms including fever, chills, and body aches.

Precautions

Do not use as a rescue medication for acute bronchospasm or asthma attack.
Use cautiously in patients with a history of cardiovascular disease, including arrhythmias and hypertension.
Monitor blood glucose in diabetic patients due to risk of hyperglycemia.
Patients with history of seizures should be monitored carefully.
Caution in individuals with weakened immune system or ongoing infections, especially tuberculosis or fungal infections.
Avoid exposure to chickenpox or measles; inform physician immediately if exposed.
Regularly monitor growth in children using inhaled corticosteroids.
Taper systemic corticosteroids gradually; do not stop abruptly when switching to or adding Symbicort.
Monitor electrolytes to detect potential hypokalemia in at-risk patients.
Avoid use in patients allergic to budesonide, formoterol, or any excipients.
Assess hepatic function due to potential for increased systemic exposure.
Rinse mouth after inhalation to reduce risk of candidiasis and irritation.
Use with caution in patients with glaucoma, cataracts, or vision disturbances.
Patients should inform healthcare providers of all medications to avoid drug interactions.
Pregnant or breastfeeding women should weigh treatment benefits versus risks; use only if clearly needed.

Warnings

Not indicated for relief of acute bronchospasm or asthma attacks; seek immediate therapy with a short-acting bronchodilator.
Possible increased risk of asthma-related death with LABA monotherapy; combination with corticosteroid mitigates this risk.
Discontinue if paradoxical bronchospasm occurs; may be life-threatening.
Risk of systemic corticosteroid side effects including adrenal suppression, especially with high doses or prolonged use.
May cause immunosuppression, increasing risk of serious infections including tuberculosis, fungal infections, and pneumonia.
Patients with worsening respiratory symptoms or insufficient control should seek medical evaluation promptly.
Can cause hypokalemia which may exacerbate cardiac arrhythmias in susceptible patients.
Overuse or overdose can result in cardiovascular adverse effects such as chest pain and tachyarrhythmias.
Avoid exposure to infections; immunization status should be reviewed prior to initiation.
Inhaler canister may explode if exposed to heat or flame; store properly.
Avoid use with other LABA-containing products to prevent overdose and serious cardiac events.
Children using Symbicort require close monitoring for growth and adrenal function.
Monitor for eye disorders such as glaucoma and cataracts with prolonged corticosteroid use.
Seek immediate medical attention if signs of allergic reaction develop.
Do not exceed recommended dose; excessive dosing can be life-threatening.

Contraindication

Known hypersensitivity or allergy to budesonide, formoterol, or any formulation components.
Primary use as a rescue inhaler for acute bronchospasm is contraindicated.
Use of formoterol monotherapy in asthma without corticosteroid is contraindicated due to increased risk of asthma-related death; Symbicort contains both components and is indicated appropriately.
Patients with severe hypersensitivity reactions to milk proteins (in certain formulations) should avoid use.
Contraindicated in patients with untreated systemic fungal infections.
Severe cardiovascular disorders where beta-agonist may pose risk should avoid use unless benefits outweigh risks.
Not approved for use in children younger than 6 years.
Situations where inhaler use is not possible or unsafe, such as inability to use inhalation device properly.
Known narrow-angle glaucoma untreated or severe ocular hypertension.
Severe osteoporosis or adrenal insufficiency requiring specialized corticosteroid management.

Drug Interactions

Concomitant use with other long-acting beta2-agonists (LABAs) increases risk of cardiovascular side effects and overdose.
Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) may increase budesonide plasma concentrations, raising risk of systemic corticosteroid effects.
Beta-blockers (non-selective and selective) may antagonize the bronchodilatory effects of formoterol and potentially induce bronchospasm.
Diuretics causing hypokalemia (e.g., thiazides, loop diuretics) may exacerbate formoterol-induced hypokalemia.
Monoamine oxidase inhibitors and tricyclic antidepressants may potentiate cardiovascular effects of formoterol.
Corticosteroids may interact with vaccines; immunosuppression can reduce vaccine efficacy.
Concomitant use of corticosteroids and other immunosuppressants enhances infection risk.
Agents that prolong QT interval may synergistically increase arrhythmia risk when combined with formoterol.
Use with other systemic corticosteroids requires monitoring for additive effects and adrenal suppression.
Symbicort’s interaction with herbal supplements (e.g., St John's Wort) may affect metabolism.
Other inhaled corticosteroids or beta-agonists increase cumulative corticosteroid and sympathomimetic exposure.
Certain antifungal agents and macrolide antibiotics inhibiting CYP3A4 may increase budesonide exposure.
Patients should inform about over-the-counter medications to avoid unrecognized interactions.
Monitoring is recommended during transition or combination with other asthma/COPD therapies.
Electrolyte imbalances from drugs and Symbicort combination require close surveillance.

Preparations Of The Drug

Symbicort inhaler containing budesonide 80 mcg and formoterol fumarate 4.5 mcg per actuation.
Symbicort inhaler with budesonide 160 mcg and formoterol fumarate 4.5 mcg per actuation.
Symbicort Aerosphere inhaler with budesonide 160 mcg and formoterol fumarate 4.8 mcg per actuation.
Metered-dose inhaler device with dose counter indicating remaining inhalations.
Foil pouch packaging for protection prior to first use to maintain stability and prevent moisture exposure.
Available in multi-dose canisters designed for twice daily administration.
Accompanied by patient instructions for priming, cleaning, and use to optimize drug delivery.
Spacers or holding chambers which may be used with Symbicort inhalers under medical advice.
Packaging includes warnings and storage instructions to maintain inhaler integrity and safety.
Manufactured under regulatory FDA approval with quality control to ensure consistent dosage delivery.
Approved for prescription use only with designated dosing devices.
Provided with detailed medication guides for patient education on proper use and precautions.
Certain formulations include propellants compliant with current environmental regulations.
Design optimized for pulmonary drug delivery targeting small and large airways.
Supplied in various strength combinations to tailor therapy to disease severity and patient response.